Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer Gene Ther. 2011 Nov 25;19(3):202–211. doi: 10.1038/cgt.2011.82

Figure 4.

Figure 4

Poly(I) reduces uptake of MV particles by the liver and spleen, enhancing bioavailability of MV in the blood of mice. CD46-negative and CD46-positive mice were injected intravenously with PBS or 0.2 mg poly(I) per mouse 5 min prior to administration of 106 TCID50 DiI-MV-Luc. (a) Numbers of red fluorescent cells (due to uptake of DiI-MV) in liver and spleen cryosection were counted (pixels) using the Image J software. Data is presented as a percentage of that in mice given MV only. Blood from (b) CD46-negative or (c) CD46-positive mice were collected at 2, 5, 10 and 30 min after MV injection and analyzed for infectious virus by TCID50 assay. Results are expressed as mean ± SD (n=3 mice). *indicate statistically different (p<0.05) against no poly(I).